Results 201 to 210 of about 631,547 (339)
Commentary on aptamers for virus research
Yasuyuki eMiyazaki, Mikako eFujita
doaj +1 more source
Development of Enhanced Separation Techniques for Oligonucleotides Utilizing Mixed-Mode Chromatography and 2D-LC/UV/MS Analysis. [PDF]
Haglöf J, Nilsson JM, Ludvigsson JW.
europepmc +1 more source
PCSK9 acts as a molecular chaperone promoting LIN28A lysosomal degradation. LIN28A elevates transcription factor HES5, increasing JMY expression. PCSK9 loss causes neural tube defects (NTDs) by disrupting the LIN28A/HES5/JMY axis, and high JMY disorganizes the neural progenitor cell microfilament network, leading to incomplete neural tube structure in ...
Xiaoshuai Li +6 more
wiley +1 more source
Unlocking atom-specific radiotherapy - DNA backbone breakage caused by X-ray photoactivation. [PDF]
Svensson PHW +15 more
europepmc +1 more source
NEAT1 Promotes Epileptogenesis in Tuberous Sclerosis Complex
The primary neurological manifestations of tuberous sclerosis complex (TSC) are intractable epilepsy and intellectual disability. NEAT1 is differentially expressed in TSC‐related epilepsy and influences neuronal excitability by regulating the PI3K/AKT/mTOR signaling pathway.
Suhui Kuang +8 more
wiley +1 more source
Label-free technique for universal and sequence independent detection of oligonucleotides and nuclease activity. [PDF]
Gooran N +4 more
europepmc +1 more source
Solid-phase oligonucleotide synthesis: a renaissance
Michael J. Gait, R. C. Sheppard
openalex +2 more sources
GSK461364 Inhibits NLRP3 Inflammasome by Targeting NEK7 Phosphorylation
Schematic diagram of the mechanism by which GSK461364 inhibits NLRP3 inflammasome activation. GSK461364 inhibits the phosphorylation of NEK7 likely at serine 221 and serine 260 by suppressing the activity of PLK1, thereby restraining the formation of the NLRP3 inflammasome.
Ruiheng Luo +13 more
wiley +1 more source
ASOG: AntiSense Oligonucleotide Generator. [PDF]
Kimi J +6 more
europepmc +1 more source
TSHR‐Targeting Nucleic Acid Aptamer Treats Graves' Ophthalmopathy via Novel Allosteric Inhibition
This study presents YC3, a novel inhibitory TSHR‐targeting aptamer, as a promising therapeutic for Graves' ophthalmopathy (GO). YC3 suppresses pathological phenotypes in human orbital fibroblasts and improves outcomes in GO mice by binding to a previously unidentified allosteric site on TSHR, demonstrating the potential of aptamers in advancing ...
Yanchen Zhang +16 more
wiley +1 more source

